Novartis to Spin Off, List Sandoz Drugs Business

  • 📰 WSJhealth
  • ⏱ Reading Time:
  • 10 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 53%

Business News News

Business Business Latest News,Business Business Headlines

Novartis is planning to spin off its generics-and-biosimilars division Sandoz and list it as a stand-alone company in Switzerland

President Biden in mid-August signed into law sweeping legislation aimed at lowering prescription drug prices and boosting the renewable-energy sector. The bill also imposes new taxes on large corporations to reduce the federal deficit. Photo: Mandel Ngan/AFP/Getty ImagesNovartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as a stand-alone company in Switzerland, a move Novartis said will enable it to focus on innovative medicines.

The Swiss pharmaceutical company said Thursday that Sandoz would be based in Switzerland and listed on the SIX Swiss Exchange, with an American depositary receipt program in the U.S.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 413. in BUSİNESS

Business Business Latest News, Business Business Headlines